Vimarsana
Biggest News Aggregation in the World

Page 33 - Odest News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Odest. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Odest Today - Breaking & Trending Today

Major Averages Holding On To Modest Gains In Early Afternoon Trading - Vimarsana News

Major Averages Holding On To Modest Gains In Early Afternoon Trading

Major Averages Holding On To Modest Gains In Early Afternoon Trading WASHINGTON (dpa-AFX) - Buying interest has waned from earlier in the session, but stocks remain mostly positive in early afternoon trading on Thursday. With the upward move, the major averages are adding to the gains posted in the previous session. Currently, the major averages are holding on to modest gains. The Dow is up 151.17 points or 0.4 percent at 34,474.22, the Nasdaq is up 28.01 points or 0.2 percent at 13,766.00 and the S&P 500 is up 13.66 points or 0.3 percent at 4,209.65. The strength on Wall Street may partly re...

U.S. Stocks Seeing Modest Strength Amid Optimism About Reopening - Vimarsana News

U.S. Stocks Seeing Modest Strength Amid Optimism About Reopening

WASHINGTON (dpa-AFX) - Stocks are seeing modest strength in morning trading on Wednesday, partly offsetting the slightly lower close seen in the previous session. The tech-heavy Nasdaq has climbed

ABN AMRO reports modest loss of EUR 54 million in the first quarter - Vimarsana News

ABN AMRO reports modest loss of EUR 54 million in the first quarter

ABN AMRO reports modest loss of EUR 54 million in the first quarter in the first quarter million Operational performance Full-year cost of risk of 25-30 basis points ; Robert Swaak, CEO, comments: " Last month, we accepted a settlement offer of EUR 480 million from the Dutch Public Prosecution Service as the outcome We are fully committed to our moderate risk profile and our role as a gatekeeper of the financial system on Our m , . We are making good progress in winding down the CIB non-core business, supported by the recently announced disposal of We continue to navigate the bank...

Destiny Pharma inks agreement with US health institutes to evaluate XF-73 drug | 15 March 2021 - Vimarsana News

Destiny Pharma inks agreement with US health institutes to evaluate XF-73 drug | 15 March 2021

15 March 2021 | 09:49am StockMarketWire.com - Biotechnology company Destiny Pharma said it had entered into an agreement under which the US government's National Institute of Allergy and Infectious Diseases would evaluate the formulation of the company's drug to prevent postsurgical staphylococcal infections. Destiny Pharma would utilize preclinical National Institute of Allergy and Infectious Diseases services programme to complete the preclinical safety studies that would support the planned clinical development in serious wound infections. Destiny Pharma will provide the XF-73 formulation...

Director Deals - Destiny Pharma PLC (DEST) | 8 January 2021 - Vimarsana News

Director Deals - Destiny Pharma PLC (DEST) | 8 January 2021

Director Deals 8 January 2021 | 06:03am StockMarketWire.com - Philip Rodgers, Chairman, bought 9,000 shares in the company on the 6th January 2021 at a price of £0.88. The Director now holds 47,462 shares. Story provided by StockMarketWire.com Director deals data provided by www.sharesmagazine.co.uk Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. Latest share price and company details: